Special Counsel Brian Sylvester was quoted in a Food Navigator-USA article, “FDA report on CBD seen as ‘disappointing’ recap of status quo,” about a report to Congress on CBD by FDA Commissioner Dr. Stephen Hahn.
Sylvester said the report suggests that FDA may be more focused on dietary supplements as a lawful regulatory pathway. “With the release of FDA’s report, we now know that FDA currently views dietary supplements as a potentially more viable pathway than food,” he said.
Related News
February 6, 2026
In the News
Louis Lehot Featured for Insights on Evolution of Dealmaking
Foley & Lardner LLP partner Louis Lehot highlighted the evolution of dealmaking in the Silicon Valley Business Journal article, "The Old Playbook Doesn't Work Anymore."
February 6, 2026
In the News
Gregory Husisian on What U.S.-India Trade Deal Means for Fashion Supply Chains
Foley & Lardner LLP Gregory Husisian discussed the broader geopolitical evolution of the US-India agreement in the Vogue Business article, “What the US-India Trade Deal Could Mean for Fashion’s Supply Chains.”
February 2, 2026
In the News
Aaron Maguregui Outlines AI Regulation and Pharma Challenges in Health Care
Foley & Lardner LLP partner Aaron Maguregui examining the regulatory landscape for AI in the health care industry in the PharmaVoice article, “As artificial intelligence increasingly takes on new patient-facing roles, laws lag behind.”